Initiation of CFTR Modulator

Phase 3Small molecule

CChildren's Hospital Medical Center, Cincinnati

Initiation of CFTR Modulator is one of 41 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisCompleted

Cystic FibrosisPhase 3

Completed

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Biaxin

AbbVie

Phase 2

2 3

Zyvox

Pfizer

Phase 2

2 4

Avelox

Bayer

Phase 2

1 5

Mycobutin

Pfizer

Phase 2

1 6

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 7

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

19 8

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 9

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 10

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Cystic Fibrosis

NCT04467957

Clinical

Trials by Indication[1]

Cystic Fibrosis2 trials

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Active, not recruiting·—·Phase 4·NCT04467957·26 enrolled

Hyperpolarized Imaging for New Treatments (HyPOINT) Study

Completed·CChildren's Hospital Medical Center, Cincinnati·Approved·NCT04259970·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Initiation of CFTR Modulator. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Initiation of CFTR Modulator compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Initiation of CFTR Modulator. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Hospital Medical Center, Cincinnati company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChildren's Hospital Medical Center, Cincinnati

Initiation of CFTR Modulator

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cystic Fibrosis2 trials

References

Drug Info

Quick Facts

Related News